Is Viridian Therapeutics Stock a Good Investment?
Viridian Therapeutics Investment Advice | VRDN |
- Examine Viridian Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Viridian Therapeutics' leadership team and their track record. Good management can help Viridian Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Viridian Therapeutics' business and its evolving consumer preferences.
- Compare Viridian Therapeutics' performance and market position to its competitors. Analyze how Viridian Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Viridian Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Viridian Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Viridian Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Viridian Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Viridian Therapeutics Stock
Researching Viridian Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 3.57. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020.
To determine if Viridian Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Viridian Therapeutics' research are outlined below:
| Viridian Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (304.27 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Is Viridian Therapeutics Inc. stock attractive for growth ETFs - July 2025 Price Swings High Return Trade Guides - newser.com |
Viridian Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Viridian Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Viridian Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Viridian Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Viridian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Viridian Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2025-05-06 | 2025-03-31 | -1.1 | -0.869 | 0.231 | 21 | ||
2025-02-25 | 2024-12-31 | -1.0442 | -0.81 | 0.2342 | 22 | ||
2024-05-08 | 2024-03-31 | -1.1 | -0.79 | 0.31 | 28 |
Know Viridian Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viridian Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viridian Therapeutics backward and forwards among themselves. Viridian Therapeutics' institutional investor refers to the entity that pools money to purchase Viridian Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-06-30 | 2.6 M | Novo A/s | 2025-06-30 | 2.4 M | Maverick Capital Ltd | 2025-06-30 | 2.3 M | Alliancebernstein L.p. | 2025-06-30 | 1.9 M | Eversept Partners, Llc | 2025-06-30 | 1.9 M | Baker Bros Advisors Lp | 2025-06-30 | 1.7 M | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Loomis, Sayles & Company Lp | 2025-06-30 | 1.3 M | Parkman Healthcare Partners Llc | 2025-06-30 | 1.3 M | Fmr Inc | 2025-06-30 | 12.2 M | Blackrock Inc | 2025-06-30 | 5.5 M |
Viridian Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.1 B.Market Cap |
|
Viridian Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.40) | (0.38) |
Determining Viridian Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Viridian Therapeutics is a good buy. For example, gross profit margin measures Viridian Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Viridian Therapeutics' profitability and make more informed investment decisions.
Evaluate Viridian Therapeutics' management efficiency
Viridian Therapeutics has return on total asset (ROA) of (0.3977) % which means that it has lost $0.3977 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6588) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of October 2025, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 29th of October 2025, Non Currrent Assets Other is likely to grow to about 992.8 K, while Non Current Assets Total are likely to drop about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.89 | 6.11 | |
| Tangible Book Value Per Share | 9.89 | 6.11 | |
| Enterprise Value Over EBITDA | (4.60) | (4.83) | |
| Price Book Value Ratio | 1.94 | 3.81 | |
| Enterprise Value Multiple | (4.60) | (4.83) | |
| Price Fair Value | 1.94 | 3.81 | |
| Enterprise Value | 803.7 M | 843.9 M |
Management at Viridian Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.543 |
Basic technical analysis of Viridian Stock
As of the 29th of October, Viridian Therapeutics has the Risk Adjusted Performance of 0.1061, coefficient of variation of 656.34, and Semi Deviation of 2.48. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viridian Therapeutics, as well as the relationship between them.Viridian Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viridian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viridian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viridian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viridian Therapeutics' Outstanding Corporate Bonds
Viridian Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viridian Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viridian bonds can be classified according to their maturity, which is the date when Viridian Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Viridian Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Viridian Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1061 | |||
| Market Risk Adjusted Performance | 0.3248 | |||
| Mean Deviation | 2.56 | |||
| Semi Deviation | 2.48 | |||
| Downside Deviation | 2.77 | |||
| Coefficient Of Variation | 656.34 | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.76 | |||
| Information Ratio | 0.1231 | |||
| Jensen Alpha | 0.3559 | |||
| Total Risk Alpha | 0.0514 | |||
| Sortino Ratio | 0.1459 | |||
| Treynor Ratio | 0.3148 | |||
| Maximum Drawdown | 16.0 | |||
| Value At Risk | (3.97) | |||
| Potential Upside | 6.39 | |||
| Downside Variance | 7.66 | |||
| Semi Variance | 6.13 | |||
| Expected Short fall | (3.12) | |||
| Skewness | 0.1293 | |||
| Kurtosis | 0.0697 |
| Risk Adjusted Performance | 0.1061 | |||
| Market Risk Adjusted Performance | 0.3248 | |||
| Mean Deviation | 2.56 | |||
| Semi Deviation | 2.48 | |||
| Downside Deviation | 2.77 | |||
| Coefficient Of Variation | 656.34 | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.76 | |||
| Information Ratio | 0.1231 | |||
| Jensen Alpha | 0.3559 | |||
| Total Risk Alpha | 0.0514 | |||
| Sortino Ratio | 0.1459 | |||
| Treynor Ratio | 0.3148 | |||
| Maximum Drawdown | 16.0 | |||
| Value At Risk | (3.97) | |||
| Potential Upside | 6.39 | |||
| Downside Variance | 7.66 | |||
| Semi Variance | 6.13 | |||
| Expected Short fall | (3.12) | |||
| Skewness | 0.1293 | |||
| Kurtosis | 0.0697 |
Consider Viridian Therapeutics' intraday indicators
Viridian Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Viridian Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Viridian Therapeutics Corporate Filings
F4 | 27th of October 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of October 2025 Other Reports | ViewVerify | |
8K | 21st of October 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
ASR | 5th of September 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Viridian Stock media impact
There is far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. This information is accessible both publicly - through Viridian Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Viridian-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Viridian Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Viridian Therapeutics Maximum Pain Price Across January 16th 2026 Option Contracts
Viridian Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Viridian Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Viridian Therapeutics' options.
Viridian Therapeutics Corporate Management
| Kyle Haraldsen | Chief Officer | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile | |
| Jonathan MBA | CEO, CoFounder | Profile | |
| Shan Wu | Chief Officer | Profile | |
| Vahe Bedian | CoFounder Scientist | Profile | |
| Lara Meisner | Sr Counsel | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.57) | Revenue Per Share | Quarterly Revenue Growth 0.042 | Return On Assets | Return On Equity |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Viridian Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.